Home > Investor Relations
Achillion is focused on solutions for the most challenging problems in infectious disease.
The investor pages that follow are your resource for financial information about Achillion Pharmaceuticals. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.
Nov 25, 2014
Nov 8, 2014
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)